RxDoctor Payments Data

Jun Yang, MD

Psychiatry · Alhambra, CANPI 1043440084

Payments from drug & device makers

$7,288in general payments, 2019–2025

Across 310 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$899
  • Siemens Medical Solutions USA, Inc.$582
  • Sunovion Pharmaceuticals Inc.$456
  • plus $512 from 5 others

What the payments were for

  • Travel & lodging$4156%
  • Food & beverage$6,79493%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,288 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$128,807
Medicare patients
230
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate63$169,770
VraylarCariprazine Hcl79$125,271
AristadaAripiprazole Lauroxil36$79,675
AustedoDeutetrabenazine13$67,971
LatudaLurasidone Hcl30$41,253
RexultiBrexpiprazole27$37,135
NamzaricMemantine Hcl/Donepezil Hcl44$26,743
Aripiprazole170$19,709
CaplytaLumateperone Tosylate11$16,166
TrintellixVortioxetine Hydrobromide30$14,124
Quetiapine Fumarate523$9,448
Memantine Hcl ErMemantine Hcl69$8,998
Olanzapine475$7,832
Fluoxetine Hcl999$6,296
Bupropion XlBupropion Hcl221$5,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,182$169,77063 claims
AbbVieVraylar, Namzaric$1,255$152,014123 claims
Alkermes, Inc.Aristada$2,401$79,67536 claims
Sunovion Pharmaceuticals Inc.Latuda$456$41,25330 claims
Otsuka America Pharmaceutical, Inc.Rexulti$232$37,13527 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$112$16,16611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$14,12430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →